Table 2.
HRs (95% CI) for renal events by combined class of calcium channel blocker medications added on to ACEIs compared with thiazide diuretics
| Variables | eGFR reduction by ≥30% from the baseline | CHR (95% CI) | P value | AHR (95% CI) | P value | |
| Yes | No | |||||
| Sex | ||||||
| Male | 29 | 160 | 1 | 1 | ||
| Female | 51 | 164 | 1.449 (0.917 to 2.289) | 0.112 | 1.444 (0.907 to 2.300) | 0.122 |
| Type of BP lowering agent added on ACEIs | ||||||
| HCT | 55 | 147 | 1 | 1 | ||
| CCBs | 25 | 177 | 0.497 (0.309 to 0.798) | 0.004 | 0.436 (0.268 to 0.711) | 0.001 |
| Aspirin (ASA) | ||||||
| No | 61 | 276 | 1 | 1 | ||
| Yes | 19 | 48 | 1.5 (0.896 to 2.511) | 0.123 | 1.422 (0.827 to 2.446) | 0.203 |
| DM duration | ||||||
| <9 years | 46 | 166 | 1 | 1 | ||
| ≥9 years | 34 | 158 | 0.755 (0.484 to 1.177) | 0.214 | 0.858 (0.544 to 1.356) | 0.513 |
| SBP baseline (mm Hg) | ||||||
| <150 | 48 | 235 | 1 | 1 | ||
| ≥150 | 32 | 89 | 1.816 (1.159 to 2.845) | 0.009 | 1.93 (1.204 to 3.094) | 0.006 |
| DBP last | ||||||
| <88 | 61 | 262 | 1 | 1 | ||
| ≥88 | 19 | 62 | 1.408 (0.840 to 2.361) | 0.194 | 1.592 (0.937 to 2.705) | 0.086 |
| Macrovascular (ASCVDs) complications | ||||||
| No | 68 | 309 | 1 | 1 | ||
| Yes | 12 | 15 | 2.464 (1.333 to 4.554) | 0.004 | 1.898 (0.866 to 4.161) | 0.109 |
Bold values indicated significant at p<0.05.
ACEIs, ACE inhibitors; AHR, adjusted HR; ASCVDs, atherosclerotic cardiovascular disease; BP, blood pressure; CCBs, calcium channel blockers; CHR, crude HR; DBP, diastolic blood pressure; DM, diabetes mellitus; eGFR, estimated glomerular filtration rate; HCT, hydrochlorothiazide; SBP, systolic blood pressure.